# RECEIVED CENTRAL FAX CENTER

OCT 3 1 2005

Docket 17501CON (AP)

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of

Chang et al

Customer No.: 051957 Serial No.: 10/685,941

Filed: October 14, 2003

For: COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC

USE

Group Art Unit: Not known

Confirmation No. 7685

Examiner: Brian Y-S. Kwon

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Attn: Supplemental Information Disclosure Statement Commissioner for Patents P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant wishes to call to the attention of the Examiner the document cited on the accompanying PTO Form 1449. No concession is made that this document is prior art, and applicant expressly reserves the right to antedate the document as may be appropriate. Applicant requests that this document be made of record in the above-identified application.

In view of the above, applicant submits that this Supplemental Information Disclosure Statement is to be considered under 37 CFR 1.97 (d).

## CERTIFICATE OF FACSIMILE

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed therein, are being faxed to the Central Fax Number 571-273-8300 on 101311035 by Bonnie Ferguson 4 pages

tof 8

Docket 17501CON (AP)

Serial No. 10/685,941

If there is a fee associated with this submission, authorization is given to charge Deposit Account 01-0885 for the fee set forth in 37 CFR 1.17 (p).

Respectfully submitted,

Date: 10/31/05

Brent A. Johnson

Patent Agent

Registration Number 51,851

Please direct all inquiries and correspondence to:

Brent A. Johnson-T2-7H Allergan, Inc. 2525 Dupont Drive, T2-7H Irvine, California 92612

Tel: (714) 246-4348 Fax: (714) 246-4249

From-ALLERGAN LEGAL DEPARTMENT Oct-31-05 01:16pm

+714-246-4249

T-603 P.03/04 F-001

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Sheet 1 of 1

FORM PTO-1449 LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17501CON(AP)	SERIAL NO.: 10/685,941
APPLICANT:	Chang et al	TITLE: COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE
FILING DATE:	October 14, 2003	GROUP: Not Known

#### **U.S. PATENT DOCUMENTS**

*EXAMINER	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (If applicable)
						,
				<u> </u>		

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
7						
				_		
		1			L	

### OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

	RA	Craven et al, "Efficacy and Safety of the IOP-Lowering Fixed Combination
l i	-	Clavellet at. Ellicacy and dalety of the for "Lowolling" wood dollar interest
1		
1		Brimonidine 0.2%/Timolol 0.5%, M200510403E.1.doc, one page
1		Dilitionality 0:276 Titioto: 0:076; 17/200

DATE CONSIDERED **EXAMINER** \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.